Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
XOMA Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
XOMA
Nasdaq
8731
https://www.xoma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for XOMA Corp
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
- Apr 25th, 2024 11:30 am
Actym Therapeutics Appoints Thomas Smart as CEO
- Apr 24th, 2024 1:00 pm
XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years
- Apr 20th, 2024 1:11 pm
XOMA Corporation Announces Closing of Tender Offer
- Apr 3rd, 2024 1:00 pm
XOMA Declares Quarterly Preferred Stock Dividends
- Mar 21st, 2024 11:30 am
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
- Mar 19th, 2024 8:05 pm
XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023
- Mar 8th, 2024 1:12 pm
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
- Mar 8th, 2024 12:30 pm
XOMA to Present at Upcoming Investor Conferences in March
- Feb 28th, 2024 12:30 pm
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
- Feb 16th, 2024 1:00 pm
With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors
- Jan 20th, 2024 2:26 pm
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
- Jan 18th, 2024 1:30 pm
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
- Jan 11th, 2024 9:05 pm
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
- Jan 8th, 2024 12:30 pm
XOMA Announces Stock Repurchase Program of up to $50 Million
- Jan 2nd, 2024 12:30 pm
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
- Dec 19th, 2023 12:30 pm
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
- Nov 7th, 2023 12:30 pm
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
- Oct 31st, 2023 11:30 am
Investing in XOMA (NASDAQ:XOMA) five years ago would have delivered you a 32% gain
- Oct 23rd, 2023 2:40 pm
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 11:30 am
Scroll